Advertisement

Proteomic Analysis of Low-Grade Serous Ovarian Cancer and Comparing It with Non-cancerous Ovarian

  • Haniyeh Bashizadeh Fakhar
  • Mostafa Rezaie-Tavirani
  • Hakimeh Zali
  • Roya Faraji Darkhaneh
  • Ehsan Kazem Nejad
  • Mohammad Hossein Aghazadeh
Original Article
  • 28 Downloads

Abstract

Background

In Iran, ovarian cancer is the eighth most common cancer. Serous is considered as the most common of all ovarian cancers. It is usually deadly due to late diagnosis. Moreover, as all studies so far have considered metastatic or high-stage ovarian cancer, this study sought low-grade ovarian serous in human, which is of high importance and aimed at obtaining protein biomarkers that may be useful in diagnosis and treatment of ovarian serous cancer.

Materials and Methods

In this experimental study, ten patients with proved low-grade serous ovarian cancer and ten women without ovarian cancer, healthy, and cancerous tissue samples were obtained to perform proteomics. All tissue proteins were purified using standard separation methods, and proteins were separated using two-dimensional electrophoresis. Healthy and tumorous tissue proteomes were compared, and the extent of protein expression was analyzed.

Results

This study identified 212 proteins, 41 of which had changes in protein expression in cancer state. The expression of eight proteins was suppressed, and five proteins were expressed in cancerous group. Thirteen proteins in cancer sample showed increase in expression and 15 proteins reduced expression in cancerous tissue.

Conclusion

It seems that in this disease, the expression of a large number of proteins in cancerous tissues changed, most of them decreased or not expressed at all. These changed proteins can be effective as biomarker in diagnosis and treatment of this disease.

Keywords

Proteomics Low-grade serous ovarian cancer Comparison Non-cancerous ovarian 

Notes

Authors’ contributions

All authors had equal role in design, work, statistical analysis, and manuscript writing.

Funding

This study was funded by Guilan University of Medical Sciences.

Compliance with Ethical Standards

Conflict of interest

The authors declare that they have no conflict of interest.

Human and Animal Rights

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Also ethics committee of Shahid Beheshti University of Medical Sciences approved this study by IR.SBMU.RETECH.REC.1396.709.

Informed Consent

Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. Cancer J Clin. 2010;60:277–300.CrossRefGoogle Scholar
  2. 2.
    Nouri D, Roshvand Z. Molecular genetics gene therapy in ovarian cancer. J Onabad Med Univ. 2003;16(3):5–20.Google Scholar
  3. 3.
    Motevali Zadeh A, Aslani F, Lakpour N. Application of genomics and proteomics technologies for early detection of cancers of the reproductive system. J Fertil Infertil. 2004;10:259–78.Google Scholar
  4. 4.
    National Institutes of Health, U.S. Department of Health and Human Services, Last updated October 2011. http://www.cancer.gov/aboutnci/servingpeople/cancer-statistics/snapshots.
  5. 5.
    Ghayuori A, Betash N, Fakhr F. Early symptoms of ovarian cancer in young women: a case–control study in oncology ward of Imam Khomeini hospital. J Med Counc Islam Repub Iran. 2003;24(3):250–6.Google Scholar
  6. 6.
    Arab M, Khayamzadeh M, Hashemi M, Hosseini M, Tabatabaeefar M, Anbiaee R, Anvari N, Ebrahimi M, Akbari ME. Crude and age-specific incidence rate patterns for histopathologic subtypes of ovarian cancer in Iran. Arch Iran Med. 2010;13(3):203–8.PubMedGoogle Scholar
  7. 7.
    Holschneider CH, Berek JS. Ovarian cancer: epidemiology, biology, and prognostic factors. Semin Surg Oncol. 2000;19:3–10.CrossRefPubMedGoogle Scholar
  8. 8.
    Lee JM, Kohn EC. Proteomics as a guiding tool for more effective personalized therapy. Ann Oncol. 2010;21(Suppl 7):vii205–10.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Wulfkuhle JD, Liotta LA, Petricoin EF. Proteomic applications for the early detection of cancer. Nat Rev Cancer. 2003;3(4):267–75.CrossRefPubMedGoogle Scholar
  10. 10.
    Jones CM, Monge ME, Kim J, Matzuk MM, Fernández FM. Metabolomic serum profiling detects early-stage high-grade serous ovarian cancer in a mouse model. J Proteome Res. 2015;14(2):917–27.CrossRefPubMedGoogle Scholar
  11. 11.
    Longuespée R, Gagnon H, Boyon C, Strupat K, Dauly C, Kerdraon O, Ighodaro A, Desmons A, Dupuis J, Wisztorski M, Vinatier D, Fournier I, Day R, Salzet M. Proteomic analyses of serous and endometrioid epithelial ovarian cancers—cases studies—molecular insights of a possible histological etiology of serous ovarian cancer. Proteom Clin Appl. 2013;7(5–6):337–54.CrossRefGoogle Scholar
  12. 12.
    Shender V, Ms Pavlyokvuv, Arapidi GP, et al. Proteome–metabolome profiling of ovarian cancer ascites reveals novel components involved in intercellular communication. Mol Cell Proteom. 2014;13(12):3558–71.  https://doi.org/10.1074/mcp.M114.041194.CrossRefGoogle Scholar
  13. 13.
    Felix L, Natasha M, Eleftherios P, Diamandisa, Vathany K. Advances in mass spectrometry-based technologies to direct personalized medicine in ovarian cancer. Transit Proteom. 2013;5(2):76–84. Google Scholar
  14. 14.
    Beranova-Giorgianni S. Proteome analysis by two-dimensional gel electrophoresis and mass spectrometry: strengths and limitation. Trend Anal Chem. 2003;22:273–81.CrossRefGoogle Scholar
  15. 15.
    Patterson SD, Aebersold RH. Proteomics: the first decade and beyond. Nat Genet. 2003;33(Suppl):311–23.CrossRefPubMedGoogle Scholar
  16. 16.
    Reif DM, White BC, Moore JH. Integrated analysis of genetic, genomic and proteomic data. Expert Rev Proteom. 2004;1(1):67–75.CrossRefGoogle Scholar
  17. 17.
    Behbodi F, Rezaee T, Yuosef zadeh Sh, Bashizadeh Fakhar H. Studying the proteomic pattern of cancerous tissue in patients with breast cancer and comparing it with healthy breast. Zahedan J Res Med Sci. 2015;17(11):e2197.CrossRefGoogle Scholar
  18. 18.
    Chow SN, Chen RJ, Chen CH, Chang TC, Chen LC, Lee WJ, Shen J, Chow LP. Analysis of protein profiles in human epithelial ovarian cancer tissues by proteomic technology. Eur J Gynaecol Oncol. 2010;31(1):55–62.PubMedGoogle Scholar
  19. 19.
    Wang J, Zhang X, Ge X, Guo H, Xiong G, Zhu Y. Proteomic studies of early-stage and advanced ovarian cancer patients. Gynecol Oncol. 2008;111(1):111–9.CrossRefPubMedGoogle Scholar
  20. 20.
    Kim JW, Nie B, Sahm H, Brown DP, Tegeler T, You JS, et al. Targeted quantitative analysis of superoxide dismutase 1 in cisplatin-sensitive and cisplatin-resistant human ovarian cancer cells. J Chromatogr B Anal Technol Biomed Life Sci. 2010;878:700–4.CrossRefGoogle Scholar
  21. 21.
    Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, et al. Cancer statistics 2006. CA Cancer J Clin. 2006;56:106–30.CrossRefPubMedGoogle Scholar
  22. 22.
    Jinawath N, Vasoontara C, Jinawath A, Fang X, Zhao K, Yap KL, et al. Oncoproteomic analysis reveals co-upregulation ofRELA and STAT5 in carboplatin resistant ovarian carcinoma. PLoS ONE. 2010;5:e11198.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Huang HL, Hsing HW, Lai TC, Chen YW, Lee TR, Chan HT, Lyu PC, Wu CL, Chan HL. Trypsin-induced proteome alteration during cell subculture in mammalian cells. J Biomed Sci. 2010;17:36.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Timms JF, Cramer R. Difference gel electrophoresis. J Proteom. 2008;8:4886–97.CrossRefGoogle Scholar

Copyright information

© Association of Gynecologic Oncologists of India 2018

Authors and Affiliations

  • Haniyeh Bashizadeh Fakhar
    • 1
  • Mostafa Rezaie-Tavirani
    • 1
  • Hakimeh Zali
    • 2
  • Roya Faraji Darkhaneh
    • 3
  • Ehsan Kazem Nejad
    • 4
  • Mohammad Hossein Aghazadeh
    • 5
  1. 1.Proteomics Research CenterShahid Beheshti University of Medical SciencesTehranIran
  2. 2.Proteomics Research Center, School of Advanced Technologies in MedicineShahid Beheshti University of Medical SciencesTehranIran
  3. 3.Department of Obstetrics and Gynecology, Reproductive Health Research CenterGuilan University of Medical SciencesRashtIran
  4. 4.Department of Biostatistics, Guilan Road Truma Research CenterGuilan University of Medical SciencesRashtIran
  5. 5.Azad Medical UniversityTehranIran

Personalised recommendations